Hematologic Malignancies
News
Lab results may help predict complications in ALL treatment
Researchers identified factors that predict which pediatric ALL patients were likely to have a longer hospital stay after induction chemotherapy...
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
News
Mutations may be detectable years before AML diagnosis
The results suggest that monitoring strategies should be studied.
Article
Rare Cancer Misdiagnosed As Orchitis
Clinicians examine a patient who was once diagnosed with multiple myeloma but who actually had something else. ...
Conference Coverage
Is CLL chemoimmunotherapy dead? Not yet
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
Conference Coverage
Study pinpoints skin cancer risk factors after hematopoietic cell transplant
CHICAGO – Fitzpatrick skin types I and II boost risk 7- to 9-fold.
Conference Coverage
Ruxolitinib overcame lenalidomide resistance in myeloma
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
News
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
Case Reports
Novel Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1
This case highlights the appropriate use of genetic testing and supports expanding the clinical diagnosis of multiple endocrine neoplasia type 1...
News
What Makes Squamous Cell Cancers Different? Genomics May Explain
New analytic tools and data use genetic signatures to help researchers distinguish the differences among various cancers.